refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
Published 1 year ago • 467 plays • Length 6:22Download video MP4
Download video MP3
Similar videos
-
1:44
post-hoc subgroup analysis from pacific: durvalumab after crt in unresectable stage iii egfrm nsclc
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
1:50
consolidation therapy for unresectable stage iii egfr-mutant nsclc
-
3:25
impact of radiation dose to immune cells in unresectable or stage iii nsclc in the durvalumab era
-
3:25
pacific 6: durvalumab after scrt in patients with nsclc
-
6:48
durvalumab improves pfs in stage iii lung cancer
-
4:43
treating for stage iii nsclc after progression on durvalumab
-
2:10
dr. langer on the benefit of durvalumab in stage iii nsclc
-
1:24
durvalumab: the new standard of care for nsclc?
-
1:13
phase ii study of durvalumab for patients with nsclc
-
1:38
pacific-r: real-word durvalumab after chemo-rt in stage 3 nsclc
-
4:46
5-year survival outcomes from the pacific trial
-
![[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital](https://i.ytimg.com/vi/EwpYIgllxqY/mqdefault.jpg)
3:53
[lung]the role of durvalumab in patients with stage 3 lung cancer in a real hospital
-
4:37
durvalumab: a new option for stage iii nsclc patients? | davey daniel
-
5:59
targeted therapy in consolidation setting for lung cancer
-
8:16
case based panel discussion - stage 3 nsclc best schedule - durvalumab/imfinzi in varying patients
-
1:13
immunotherapy in stage iii nsclc metastatic disease
-
1:01
impact of durvalumab as consolidation therapy in nsclc
-
1:21
pacific-brazil: intensified induction chemo-io in stage iii nsclc